Aratana Therapeutics Inc (NASDAQ:PETX) insider Ernst Heinen sold 4,628 shares of the company’s stock in a transaction dated Friday, August 10th. The stock was sold at an average price of $5.15, for a total transaction of $23,834.20. Following the transaction, the insider now owns 168,020 shares of the company’s stock, valued at approximately $865,303. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Ernst Heinen also recently made the following trade(s):

  • On Wednesday, August 8th, Ernst Heinen sold 2,674 shares of Aratana Therapeutics stock. The stock was sold at an average price of $5.15, for a total transaction of $13,771.10.

Aratana Therapeutics traded up $0.06, hitting $5.14, during trading hours on Friday, according to MarketBeat. 211,201 shares of the company’s stock traded hands, compared to its average volume of 250,932. Aratana Therapeutics Inc has a 52-week low of $3.67 and a 52-week high of $7.28. The company has a quick ratio of 2.82, a current ratio of 3.02 and a debt-to-equity ratio of 0.09.

Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.05. Aratana Therapeutics had a negative net margin of 154.23% and a negative return on equity of 35.25%. The company had revenue of $4.91 million during the quarter, compared to analysts’ expectations of $4.72 million. research analysts forecast that Aratana Therapeutics Inc will post -0.48 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Franklin Resources Inc. grew its stake in Aratana Therapeutics by 0.5% during the 1st quarter. Franklin Resources Inc. now owns 5,969,371 shares of the biopharmaceutical company’s stock valued at $26,325,000 after acquiring an additional 28,969 shares in the last quarter. BlackRock Inc. grew its stake in Aratana Therapeutics by 11.5% during the 2nd quarter. BlackRock Inc. now owns 3,348,240 shares of the biopharmaceutical company’s stock valued at $14,231,000 after acquiring an additional 345,204 shares in the last quarter. General American Investors Co. Inc. grew its stake in shares of Aratana Therapeutics by 44.7% in the 1st quarter. General American Investors Co. Inc. now owns 1,617,923 shares of the biopharmaceutical company’s stock valued at $7,135,000 after buying an additional 500,000 shares during the period. Massachusetts Financial Services Co. MA grew its stake in shares of Aratana Therapeutics by 36.2% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 1,376,198 shares of the biopharmaceutical company’s stock valued at $5,849,000 after buying an additional 365,750 shares during the period. Finally, Millennium Management LLC grew its stake in shares of Aratana Therapeutics by 117.0% in the 1st quarter. Millennium Management LLC now owns 1,347,975 shares of the biopharmaceutical company’s stock valued at $5,945,000 after buying an additional 726,903 shares during the period. 67.82% of the stock is owned by institutional investors.

Several research analysts recently weighed in on PETX shares. BidaskClub downgraded shares of Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, May 31st. ValuEngine upgraded shares of Aratana Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 2nd. HC Wainwright set a $10.00 price target on shares of Aratana Therapeutics and gave the stock a “buy” rating in a research report on Monday, May 7th. Zacks Investment Research downgraded shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, July 13th. Finally, Stifel Nicolaus dropped their price objective on shares of Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, August 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $8.21.

About Aratana Therapeutics

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

Featured Story: Penny Stocks, What You Need To Know

Insider Buying and Selling by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.